A behavioral test proves that treatment of a chemotherapeutic
drug elemene can cause
hyperalgesia of a mouse along with
anxiety-like
mood; according to the present invention, it is found that the
elemene treatment activates several brain regions including a lateral septum (LS), a cingulate cortex (ACC), a paraventricular
nucleus (PVT), and a hypothalamic dorsal medial
nucleus (DMH), the most significant one of the GABA energy neurons of the LS, the most significant one of the GABA energy neurons of the LS, the most significant one of the GABA energy neurons of the LS, the most significant one of the GABA energy neurons of the LS, the most significant one of the GABA energy neurons of the LS, and the most significant one of the GABA energy neurons of the LS, the most significant one of the GABA energy neurons of the LS, the most significant one of the GABA energy neurons of the LS, the Chemical genetic inhibition and
apoptosis of LS neurons significantly reduce mouse pain and
anxiety behaviors caused by
elemene treatment, and a foundation is laid for clinical application. According to the application, the influence of elemene-induced
chemotherapy-induced
peripheral neuropathy and
anxiety is researched from the perspective of relieving the
side effect of the
medicine, and the research finds that inhibition of LS
brain region GABAergic neurons has an improvement effect in the aspects of
chemotherapy-induced
peripheral neuropathy and anxiety, and the
life quality of
cancer patients
after treatment can be better improved possibly.